Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2014 Jan;78(1):66-9. doi: 10.1016/j.diagmicrobio.2013.10.001. Epub 2013 Oct 14.

Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6')-Ib.

Author information

1
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.
2
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway; Research Group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
3
Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway. Electronic address: orjan.samuelsen@unn.no.

Abstract

In this study, we show that the increasing prevalence of aminoglycoside resistance observed in Norway among clinical Escherichia coli and Klebsiella spp. isolates is mainly due to the presence of the aminoglycoside-modifying enzymes AAC(3)-II and AAC(6')-Ib. A frequent co-association of aminoglycoside resistance with Cefotaximase-München group 1 extended-spectrum β-lactamases was also observed.

KEYWORDS:

AAC(3)-II; AAC(6′)-Ib; CTX-M; ESBL; RmtB

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center